IGC Pharma (NYSEMKT:IGC – Get Free Report) had its price target increased by equities research analysts at Ascendiant Capital Markets from $4.00 to $4.25 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.
IGC Pharma Trading Down 15.1 %
NYSEMKT IGC opened at $0.28 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.15 and a quick ratio of 0.98. The firm has a market cap of $22.07 million, a price-to-earnings ratio of -2.52 and a beta of 1.32. The stock’s 50-day moving average price is $0.33 and its 200 day moving average price is $0.36.
Institutional Trading of IGC Pharma
A number of hedge funds have recently added to or reduced their stakes in IGC. Geode Capital Management LLC raised its stake in shares of IGC Pharma by 31.0% during the third quarter. Geode Capital Management LLC now owns 562,969 shares of the company’s stock valued at $240,000 after acquiring an additional 133,142 shares during the last quarter. Fullcircle Wealth LLC bought a new position in IGC Pharma during the third quarter worth $42,000. Squarepoint Ops LLC bought a new position in IGC Pharma during the fourth quarter worth $42,000. Northern Trust Corp raised its stake in IGC Pharma by 59.7% during the fourth quarter. Northern Trust Corp now owns 113,407 shares of the company’s stock worth $38,000 after buying an additional 42,380 shares during the last quarter. Finally, Virtu Financial LLC raised its stake in IGC Pharma by 164.7% during the third quarter. Virtu Financial LLC now owns 123,060 shares of the company’s stock worth $53,000 after buying an additional 76,563 shares during the last quarter. Institutional investors and hedge funds own 3.87% of the company’s stock.
About IGC Pharma
IGC Pharma, Inc, a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development.
See Also
- Five stocks we like better than IGC Pharma
- How to Evaluate a Stock Before Buying
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- Are Penny Stocks a Good Fit for Your Portfolio?
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for IGC Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGC Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
